Kao et al showed that tumor-derived TGF-β significantly reduces the ability of DC/tumor fusion cells to prime antitumor immunity and TGF-β-blocking strategies can enhance antitumor immunity [32], [34]. Here, TGFB1 is linked to neoplasm.